TN2013000197A1 - Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
- Google Patents
Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/MX2011/000138external-prioritypatent/WO2012067481A2/en
Application filed by Posi Visionary Solutions LlpfiledCriticalPosi Visionary Solutions Llp
Publication of TN2013000197A1publicationCriticalpatent/TN2013000197A1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Medicines Containing Plant Substances
(AREA)
Abstract
The invention relates to a pharmaceutical formulation or composition intended to be administered orally in the form of a tablet, a coated tablet or a capsule, for the prevention or treatment of intestinal disorders, such as irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, digestive enzymes, a binding agent, a diluent, an adsorbent agent, a disintegrating agent, a lubricant and a glidant, effective for normalising colon transit, for providing an analgesic activity, for providing an antispasmodic activity and for reducing symptoms related to intestinal gas, such as distention, abdominal pain and flatulence.
TNP2013000197A2011-11-152013-05-06Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
TN2013000197A1
(en)
Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
ORAL PHARMACEUTICAL FORMULATION FOR TREATING IRRITABLE BOWEL SYNDROME CONTAINING TRIMEBUTIN, SIMETICON AND a-D-GALACTOSIDASE AND METHOD FOR ITS MANUFACTURE
Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER AND α-D-GALACTOSIDASE
ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER AND α-D-GALACTOSIDASE
Pharmaceutical ingredients that are administered orally for the treatment of irritable bowel syndrome. These include intestinal peristalsis, substances that prevent gas congestion, and digestive enzymes. And a method for preparing that component